Evidence map›Paper›PMID 40898667›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2025

Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.

Jieni Li, George J Hutton, Rajender R Aparasu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jieni LiDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA; Population Health Outcomes and Pharmacoepidemiology Education and Research (P-HOPER Center), University of Houston College of Pharmacy, Houston, TX, USA.
George J HuttonBaylor College of Medicine, Houston, TX, USA.
Rajender R AparasuDepartment of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA; Population Health Outcomes and Pharmacoepidemiology Education and Research (P-HOPER Center), University of Houston College of Pharmacy, Houston, TX, USA.ORCID 0000-0003-2310-901X

Funding

AHRQ HHS R01 HS029501
6 · The paper itself

Abstract

backgroundWith advances in disease-modifying therapies (DMTs), patients with multiple sclerosis (MS) are living longer.

objectiveThis study examined MS prevalence and DMT use among older adults 65 years and above in the United States.

methodsThe study analyzed 2011-2021 Medicare fee-for-service claims data.

resultsThe prevalence rate of MS in older adults increased by 15.49%, from 210.55 (per 100,000) in 2011 to 243.17 in 2021. Women comprised 75% of the aging MS population, and 90% were White. Over half were prescribed DMTs, mainly interferon-beta and glatiramer acetate.

conclusionsThe study found an increasing prevalence of MS among older adults in the United States over the past decade, with over half using DMTs. Our findings highlight the need for increasing geriatric care for MS.

Indexed as

Multiple SclerosisAgedAged, 80 and overFemaleGlatiramer AcetateHumansMaleMedicarePrevalenceUnited StatesGlatiramer Acetatedisease-modifying therapyepidemiologyMultiple sclerosisolder adults

Identifiers

PMID40898667
PMCPMC12412907

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.